Home|||||||Technical Support|

Abeta-pE3 - 218 611

A major component of neuritic plaques in Alzheimer's disease
Monoclonal mouse purified IgG
Cat. No.: 218 611
Amount: 100 µg
Price: $415.00
Cat. No. 218 611 100 µg purified IgG, lyophilized. Azide was added before lyophilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Applications WB: 1 : 1000 (see remarks) gallery  
IP: not tested yet
ICC: not tested yet
IHC: 1 : 100 (see remarks) gallery  
IHC-P/FFPE: 1 : 500 gallery  
Clone 70D7
Subtype IgG3 (κ light chain)
Immunogen Synthetic peptide corresponding to AA 3 to 7 from human Abeta-pE3 (UniProt Id: P05067)
Epitop Epitop: AA 3 to 7 from human Abeta-pE3 (UniProt Id: P05067)
Reactivity Reacts with: human (P05067), rat (P08592), mouse (P12023).
Other species not tested yet.
Specificity Recognizes specific oligomeric structures formed preferentially by Abeta-pE3.
Remarks

WB: Detects purified Abeta pE3. Complex samples like brain extracts still have to be tested.
Boil membrane after blotting for 3min.
IHC: Antigen retrieval with formic acid is required.

Data sheet 218_611.pdf
Cat. No.: 218 611
Quantity: 100 µg
Price: $415.00
Background

Amyloid deposits, also called plaques, of Alzheimer's patients consist of several protein components like the amyloid beta-peptides (Abeta, ) 1-40/42 and additional C- and N-terminally truncated and modified fragments. Very abundant are the isoaspartate (isoAsp)-Abeta and pyroglutamyl (pGlu)-Abeta peptides. The latter are formed by cyclization of the N-terminal glutamate at position 3 or 11 catalyzed by glutaminyl cyclase (QC) resulting in very amyloidogenic and neurotxic variants of Abeta; Abeta-pE3 and Abeta pE11.
In contrast to extracellular plaques that do not perfectly correlate with Alzheimer´s disease intraneuronal Abeta accumulation and vascular Abeta deposits have gained more and more evidence to be among the crucial factors responsible for progressive neuron loss.